1.Polypeptide drugs for oral administration with nanoparticles as carriers:current situation, existing problems and developmental prospects
Chinese Journal of Tissue Engineering Research 2015;(25):4091-4095
BACKGROUND:The new formulation and preparation technology of new drugs have become a hot spot for improving the utilization of polypeptides. In particular, the development of nanotechnology in recent years has promoted the clinical application of polypeptide drugs. OBJECTIVE:To review the current research of nanoparticles as carriers of polypeptide drugs for oral administration. METHODS:A computer-based search of CNKI database and SCI database was performed for relevant articles published from 1996 to 2014 by using the keywords of“protein, peptide drugs, nanoparticles, oral administration”in Chinese and English, respectively. RESULTS AND CONCLUSION:The encapsulation efficiency, release rate of drug delivery, stability of nanoparticles in the gastrointestinal tract and penetrability of the intestinal mucosa are determined by many factors, such as the kind, size, surface charge and modification of nanoparticles. The nanoparticles can increase the stability of protein drugs and improve the bioavailability of drugs. The targeting property of the nanoparticles can decrease the adverse reactions of some drugs. The release effect of the nanoparticles can decrease the dosage of drugs and increase the drug circulating time. However, there are stil many problems to be solved in nanotechnology:the activities of some protein drugs are lost in the preparation process;theencapsulation efficiency and drug loading need to be improved;protein burst release cannot be solved completely;the mass production of nanoparticles is stil difficult.
2.Study on application effect of paclitaxel combined with carboplatin neoadjuvant chemotherapy in patients with advanced cervical carcinoma
Yuhong FAN ; Huaying FANG ; Xiaohui WU
Chinese Journal of Biochemical Pharmaceutics 2017;37(4):379-381
Objective To explore the application effect of paclitaxel combined with carboplatin neoadjuvant chemotherapy in patients with advanced cervical carcinoma.Methods Forty patients with stage Ⅱa and above cervical cancer who were treated between August 2015 and August 2016 were selected as the research objectives and all patients were diagnosed by pathological examination.They were divided randomly into experimental group(n=20)and control group(n=20).Patients in the experimental group were treated with intravenous chemotherapy before operation.This scheme included paclitaxel and carboplatin.It included 2 cycles,and the interval between the 2 cycles was 3 weeks.Extensive hysterectomy and pelvic lymphadenectomy were made in 14 days after chemotherapy.The patients in the control group were treated only with extensive hysterectomy and pelvic lymphadenectomy.The efficacy of neoadjuvant chemotherapy was evaluated according to WHO criteria,and observed the operation condition.Adverse drug reactions were evaluated according to WHO anti-cancer drug adverse reaction grade.The quality of life of the two groups was evaluated by the mos item short from health survey(SF-36).Results 20 patients completed chemotherapy,CR5 cases,PR11 cases,SD3 cases,PD1 cases,and the total effective rate(CR+PR)was 80%.At the same time,The paracervical tissue becomed soft in varying degrees,the gap widened,the invasive lesions were controlled in different degrees.Adverse reactions were mild and relieved without special treatment.There was no kidney and heart function damage.All cases were operated successfully after chemotherapy.There were no significant difference in operation time and blood loss between the two groups.The rate of lymph node metastasis,the infiltration rate of uterine tissue and the residual rate of tumor tissue in the vaginal margin were lower than those in the control group(P<0.01).The SF-36 scores of the two groups were higher than those before treatment,but the score of the experimental group was higher significantly than that of the control group,and the difference was statistically significant(P<0.01).Conclusion Paclitaxel combined with carboplatin in neoadjuvant chemotherapy of cervical cancer can reduce the tumor volume,increase the chance of surgery,has less toxic side effects,lower metastatic rate and improve the quality of life of patients.It is worthy of further clinical research and recommendation.
3.Alkaloids from twigs and leaves of Picrasma quassioides
Meng CHEN ; Huaying FAN ; Shengjun DAI ; Ke LIU
Chinese Traditional and Herbal Drugs 1994;0(06):-
Objective To study alkaloids from the twigs and leaves of Picrasma quassioides. MethodsCompounds were isolated and purified by column chromatography over Sephadex LH-20 and silica gel column. Their chemical structures were elucidated on the basis of physicochemical properties and spectral data. Results Sixteen alkaloids were isolated, purified, and identified as: 5-methoxycanthin-6-one (Ⅰ), 11-hydroxycanthin-6-one (Ⅱ), canthin-6-one (Ⅲ), 4, 5-dimethoxycanthin-6-one (Ⅳ), 4-methoxy-5-hydroxycanthin-6-one (Ⅴ), 3-methylcanthin-2, 6-dione (Ⅵ), 1-formyl-4-methoxy-?-carboline (Ⅶ), 1-methoxy-?-carboline (Ⅷ), 1-ethyl-4, 8-dimethoxy-?-carboline (Ⅸ), 1-methoxycarbonyl-4-hydroxyl-?-carboline (Ⅹ), 1-methyl-4-methoxy-?-carboline (Ⅺ), 1-ethoxycarbonyl-?-carboline (ⅩⅡ), 1-formyl-?-carboline (ⅩⅢ), 1-methoxycarbonyl-?-carboline (ⅩⅣ), 1-ethyl-4-methoxy-?-carboline (ⅩⅤ), and 1, 2, 3, 4-tetrahydro-1, 3, 4-trioxo-?-carboline (ⅩⅥ). Conclusion Compound Ⅺ is separated from the natural plant for the first time and compounds Ⅱ, Ⅷ, and ⅩⅤ are separated from plants of Picrasma Bl. for the first time.
4.Exploring how to Improve the Quality Control of Medical Instrument Clinical Trials
Shan JING ; Huaying FAN ; Lijue WANG ; Hao WANG ; Yulan LIU
Chinese Journal of Medical Science Research Management 2015;28(1):5-7,12
Objective To improve the quality of medical device clinical trial.Methods To analyze medical device clinical trials conducted in our hospital from 2006 to 2010,and proposed the strategy to strengthen medical device clinical trial management.Results Most of the medical devices clinical trials were class Ⅲ medical devices clinical validation in our hospital,Surgical departments undertook most of the clinical trials.Until July 2013,49 trials were done only 56% of undertake the project.96% of completed trials were approved for medical device registration certificate.Conclusions The quality of clinical trials must be improved,andthe quality control process in medical device clinical trial should be reinforced.
5.Protective Effect of Alprostadil on Renal Graft Functions in Early Period
Pingxian WANG ; Guizhi GONG ; Huaying XU ; Chibing HUANG ; Mingqi FAN ; Genfu ZHANG
China Pharmacy 1991;0(01):-
OBJECTIVE:To assess whether Alprostadil plays a role in improving renal function of renal recipi?ents.METHODS:A randomized control clinical trial was designed between January1,2001and February28,2004.Alprostadil was administered in85renal recipients who received60?g Alprostadil while transplanting kidney and each day after opera?tion.The effects of Alprostadil were compared with the control group which included276recipients to determine the influences of Alprostadil on urine,creatinine(Cr)and creatinine clearance(Ccr).Under Doppler Ultrasound the renal blood flow resis?tance_indexes(RI)were measured.The rates of acute renal graft rejection(AR)and delayed graft function(DGF)were also calculated in both groups.RESULTS:Urine and Ccr were significantly higher in Alprostadil_treated group than in control.On the contrary Cr and RI were significantly lower in Alprostadil_treated group than in control.Alprostadil_treated group also showed a significantly lower incidence of DGF,but the incidences of rejection in both groups were equal.CONCLUSION:The findings suggest that the addition of Alprostadil to renal recipients improves early graft function and reduce the incidence of DGF,but does not influence the incidence of rejection.
6.Some Important Aspects in Medical Education
Pingxian WANG ; Guizhi GONG ; Huaying XU ; Qibing HUANG ; Mingqi FAN ; Genfu ZHANG
Chinese Journal of Medical Education Research 2003;0(04):-
Nowadays,in order to cultivate a great number of high-quality clinicians,on students it is essential for medical university to strengthen education of humanities,excite aspiration for innovating,cultivate innovation ability and teach the modern medical knowledge with science and rational method.The author has given his reasons and made suggestions for the opinion in the article.
7.Intrinsic prokaryotic promoter activity of SUMO gene and its applications in the protein expression system of Escherichia coli.
Yanhong QI ; Zhurong ZOU ; Huaying ZOU ; Yunliu FAN ; Chunyi ZHANG
Chinese Journal of Biotechnology 2011;27(6):952-962
Nowadays, SUMO fusion system is important for recombinant protein production in Escherichia coli, yet a few aspects remain to be improved, including the efficacy for vector construction and protein solubility. In this study, we found the SUMO gene Smt3 (Sm) of Saccharomyces cerevisiae conferred an unexpected activity of constitutive prokaryotic promoter during its PCR cloning, and the gene coding regions of SUMOs in most species had a sigma70-dependent prokaryotic promoter embedded, through the prediction via the BPROM program developed by Softberry. By combining the characters of Sm promoter activity and the Stu I site (added at the 3'-terminal of Sm), and introducing a His-tag and a hyper-acidic solubility-enhancing tag, we further constructed a set of versatile vectors for gene cloning and expression on the basis of Sm'-LacZa fusion gene. Experimentally started from these vectors, several target genes were subcloned and expressed through blue-white screening and SDS-PAGE analysis. The results manifest a few of expectable advantages such as rapid vector construction, highly soluble protein expression and feasible co-expression of correlated proteins. Conclusively, our optimized SUMO fusion technology herein could confer a large potential in E. coli protein expression system, and the simultaneously established co-expression vector systems could also be very useful in studying the protein-protein interactions in vivo.
Amino Acid Sequence
;
Base Sequence
;
Escherichia coli
;
genetics
;
metabolism
;
Genetic Vectors
;
genetics
;
Lac Operon
;
genetics
;
Molecular Sequence Data
;
Promoter Regions, Genetic
;
genetics
;
Recombinant Fusion Proteins
;
biosynthesis
;
genetics
;
Saccharomyces cerevisiae Proteins
;
biosynthesis
;
genetics
;
Small Ubiquitin-Related Modifier Proteins
;
biosynthesis
;
genetics
;
Sumoylation
8.Problems and countermeasures of the management of drug clinical trials' contract and fund
Huaying FAN ; Hao WANG ; Hua ZHANG
Chinese Journal of Medical Science Research Management 2018;31(3):232-235
Objective To strengthen the management of clinical trials' contracts and funds and improve the standardization of clinical trials.Methods Based on the analysis of the common problems in the management of clinical trials' contracts and funds,putting forward corresponding countermeasures and suggestions.Results Managing clinical trials' contracts and funds scientifically could protect the rights and interests of subjects and research institutions.Conclusions Strengthening the management of clinical trials' contracts and funds could improve the management of institutions and the quality of clinical trials.
9.Strengthening the management of funds to improve the quality of drug clinical trials
Lijue WANG ; Huaying FAN ; Zhenwei XIE ; Hao WANG ; Hua ZHANG
Chinese Journal of Medical Science Research Management 2019;32(2):143-145
Objective The funding management of drug clinical trials is one of the most important step in the management of clinical trials.Strengthening the management of clinical trial funds can improve the efficiency of fund utilization and ensure the smooth implementation of clinical trials.Methods This paper summarizes the problems of clinical trial fund management,proposes some main strategies for fund management based on root cause analysis.Results Through the establishment and improvement of the drug clinical trial fund management system in our hospital,the management of funds is strengthened,the trial carry out more smoothly and the result is more accurate.Conclusions Improving the management system of drug clinical trial funds and standardizing the management of clinical trials is of great significance to ensure the quality of clinical trials.Also it will improve the clinical trial management level of our hospital.
10.Improving the management level of clinical trial based on the establishment of drug clinical trial center pharmacy
Lijue WANG ; Mei WANG ; Xin'an LIU ; Huaying FAN ; Hua ZHANG ; Hao WANG ; Yulan LIU
Chinese Journal of Medical Science Research Management 2018;31(6):479-480,封3-封4
Objective To discuss our drug clinical trial institution's experience and findings during the process of establishing drug clinical trial central pharmacy.Methods Analyze the previous key issues identified during the drug management under different modes,discuss the necessity and feasibility of establishing drug clinical trial central pharmacy.Meanwhile,discuss the planning and construction of hardware including location site of the central pharmacy,equipment and facilities,staff,as well as software such as electronic management system and standard operation procedures.Results After the adoption of central trial pharmacy,space and energy are saved,manpower and material resources are saved,the quality of clinical trials also improved.Conclusions Standardized and unified management of investigational drugs through establishing drug clinical trial central pharmacy,is the strong guarantee for the drug safety of human subject,as well as the accuracy and scientificity of trial results.